# 1st Surveillance Credit rating report APU PHARMACY



Ref. no.: FR/2023/32521

#### **Report Contents:**

Particulars	Page
Rating Rationale	1
Entity Profile	2
Business Management	2
Market Review	2
Business Analysis	3
Financial Position Analysis	3
Banking Relationship	4
Risk Factor Analysis	5
Rating Observation	5

#### **Key Snapshot:**

		BDI. IN	million
	Particulars	2022	2021
ľ	Povonuo	12.65	11 50

r ai ticulai 3	2022	2021
Revenue	12.65	11.50
EBIT	1.61	1.46
Net Profit	1.27	1.16
Total Assets	9.69	8.81
Total Equity	6.22	5.66
Total debt	3.47	3.15
Net Profit Margin (%)	10.1	10.1
CCC (Days)	254	197
ICR (X)	5.22	5.22

Capital Structure (BDT. in million)



### Analysts:

Shudhan Mallick shudhan@wasocreditrating.com

Maharan Nasrin maharan@wasocreditrating.com

E ng	Rating Notch	Outlook	Date of Declaration	Date of Expiration
SME Ratin	WCRSME3	Stable	04 July 2023	03 July 2024

Methodology: SME rating methodology published on the WCRCL website at www.wasocreditrating.com

## **RATING RATIONALE**

WCRCL has reaffirmed 'WCRSEM3' (pronounced as WASO Credit Rating Small And Medium Enterprise Three) rating under the SME Rating to **Apu Pharmacy** (hereinafter referred as "AP" or "The Enterprise") based on its financial and other relevant qualitative and quantitative information upto the date of the rating issuance.

The above rating has been assigned based on the fundamentals of the enterprise which includes:

- Experienced and skilled management
- Satisfactory banking relationship
- Good business network
- Good interest coverage position
- Low levered capital structure

However, the above rating has been moderated to some extent due to some factors like:

- Tight liquidity position with long cash conversion cycle
- Low disclosure of financial statements
- Low management information system (MIS) and Manual accounting system

The SME rating implies that the enterprise is adjudged to above average credit quality.

WCRCL also viewed the enterprise with "Stable" outlook and believes that AP will be able to maintain its good fundamentals in the foreseeable future. This rating may be revised in case of any extraordinary changes in line with the sponsor's equity investment, debt obligations, management, business operations and/or changes in any macro and micro factors in the economy.